Full-Time

Associate Director/Director

Procure to Pay

Posted on 8/22/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Develops gene editing therapies for cardiovascular disease

Biotechnology
Healthcare

Senior, Expert

No H1B Sponsorship

Boston, MA, USA

Hybrid role requiring 3 days in the Boston office.

Category
Procurement & Sourcing
Supply Chain Management
Operations & Logistics
Required Skills
Coupa
Requirements
  • Bachelor’s degree in finance, accounting, economics, business, or a related field
  • At least 9 years of relevant strategic sourcing and purchasing experience with at least 4 years’ experience within the biotech industry.
  • Experience managing the accounts payable process.
  • Comprehensive knowledge of strategic sourcing best practices and proven negotiation skills.
  • Hands on system related skill, including Coupa or similar platform.
  • Solid analytical skills and solution-driven thinking; collects and researches data; uses intuition and experience to complement data.
  • Identifies and resolves problems in a timely manner; develops alternative solutions; works well in group problem solving situations; presents ideas and information in a manner that gets others’ attention.
  • Demonstrated communication and teamwork capabilities and the ability to work well across the organization.
  • Strong project management skills, including the ability to prioritize, balance and manage multiple efforts with strong results/goal orientation.
Responsibilities
  • Works closely with each function to lead, oversee and coordinate the negotiation strategies / efforts and processes on purchase agreements and vendor selection that results in quality, delivery, and cost effectiveness.
  • Partners with departments to understand purchasing needs and adequate funds are available.
  • Manages supplier relationships including developing and tracking of key performance indicators for the category of spend, facilitating key/strategic supplier-company business meetings, and supporting key operational due diligence efforts.
  • Develops strong working knowledge of spend management platform and works closely with systems consultants to continuously improve and automate new features.
  • Develops and maintains Verve’s purchasing policy; ensuring our practices are in alignment and the policy is reflective and facilitates the needs of the business.
  • Strategic oversight of the Accounts Payable function enabling streamlined processes and optimized workflow
  • Ensure timely and accurate payments to vendors, including vendor onboarding and resolution of escalation issues.
  • Oversee and properly maintain vendor records as well as required annual reporting for vendor IRS filings
  • Managerial responsibilities for a team including oversight of day-to-day work assignments and performance, mentor, provide feedback, and train team.
  • Other duties as assigned.

Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions, unlike traditional therapies that require ongoing management. The company specifically targets the PCSK9 and ANGPTL3 genes, which are known to help lower blood lipid levels. This focus on gene editing sets Verve apart from competitors who may rely on more conventional treatment methods. The goal of Verve Therapeutics is to offer potentially curative options for patients with cardiovascular diseases, improving their long-term health outcomes.

Company Stage

IPO

Total Funding

$353.6M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

1%

1 year growth

0%

2 year growth

4%
Simplify Jobs

Simplify's Take

What believers are saying

  • Eli Lilly's $60M investment shows confidence in Verve's cardiovascular gene editing approach.
  • CRISPR therapy approvals, like Casgevy, pave the way for Verve's regulatory success.
  • CRISPR's success in genetic blindness supports Verve's potential in cardiovascular treatments.

What critics are saying

  • Rapid CRISPR advancements may increase competition, affecting Verve's market share.
  • Most CRISPR therapies are in early stages, delaying Verve's market entry and revenue.
  • Verve's stock drop post-offering suggests investor concerns about financial stability.

What makes Verve Therapeutics unique

  • Verve focuses on single-course gene editing for cardiovascular diseases, unlike chronic treatments.
  • The company targets PCSK9 and ANGPTL3 genes, crucial for lowering blood lipid levels.
  • Verve's approach offers potentially curative treatments, setting it apart in the biotech sector.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

INACTIVE